The peptide and oligonucleotide cdmo global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Peptide And Oligonucleotide CDMO Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size - The peptide and oligonucleotide CDMO market size has grown rapidly in recent years. It will grow from $1.93 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.
The peptide and oligonucleotide CDMO market size is expected to see rapid growth in the next few years. It will grow to $3.39 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends in the forecast period include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report
Scope Of Peptide And Oligonucleotide CDMO MarketThe Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Peptide And Oligonucleotide CDMO Market Overview
Market Drivers -The growing adoption of personalized medicine is expected to propel the growth of the peptide and oligonucleotide CDMO markets going forward. Personalized medicine is an approach to healthcare that tailors medical decisions and treatments to individual characteristics, such as genetics, environment, and lifestyle. The growing adoption of personalized medicine is due to several factors such as advancements in genomic technologies, increased understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options tailored to individual patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a crucial role in personalized medicine by producing customized therapeutic peptides and oligonucleotides tailored to individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the peptide and oligonucleotide CDMO market.
Market Trends - Major companies operating in the peptide and oligonucleotide CDMO market are focusing on developing strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on developing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), partnered with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This partnership aims to utilize PolyPeptide's cGMP manufacturing capacities and market access, along with Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is focused on jointly exploring the development of suitable peptide candidates with the goal of more sustainable production of peptide-based APIs.
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4)
By End User: Biopharmaceutical Companies, Pharmaceutical Companies,
Research Institutes, Academic and Government Organizations, Others End
Users
Get an inside scoop of the peptide and oligonucleotide cdmo market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
Regional Insights - North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies - Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
Table of Contents
1. Executive Summary
2. Peptide And Oligonucleotide CDMO Market Report Structure
3. Peptide And Oligonucleotide CDMO Market Trends And Strategies
4. Peptide And Oligonucleotide CDMO Market – Macro Economic Scenario
5. Peptide And Oligonucleotide CDMO Market Size And Growth
…..
27. Peptide And Oligonucleotide CDMO Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment